Volnea Kit
Product Images NDC 70700-122

7 FDA label images from Xiromed, Llc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Volnea (NDC 70700-122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed, Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Fig 1)

Fig-1 (Fig 1)
A forest plot chart showing effect estimates (Odds Ratios/Relative Risks) with confidence intervals from multiple studies on contraceptive use. The x-axis is labeled 'Effect Estimate (OR/RR)' ranging from -1.5 to 2, with various studies listed on the y-axis, including the NICHD Women's Contraceptive Study, French E3N cohort, Shanghai Women's Health Study, Nurses' Health Study II, Oxford Family Planning Association Study, and Danish Sex Hormone Register Study. Each study has a corresponding point and confidence interval on the plot.*
FDA Label Image

Volnea-blister-2.jpg (Volnea Blister 2)

Volnea-blister-2.jpg (Volnea Blister 2)
An instructional illustration showing a hand removing a pill from a Volnea kit blister card. The card is organized by weeks (Week 1 through Week 4) and days of the week (Sunday to Wednesday visible), with arrows indicating the order in which to take the Desogestrel and Ethinyl Estradiol tablets. The dosage strength shown is 0.15 mg Desogestrel and 0.02 mg or 0.01 mg Ethinyl Estradiol.*
FDA Label Image

Volnea-blister-3.jpg (Volnea Blister 3)

Volnea-blister-3.jpg (Volnea Blister 3)
A medication kit diagram for Volnea, showing a weekly pill schedule for 4 weeks. Weeks 1 to 3 have white tablets arranged by day from Sunday to Saturday, marked Week 1, Week 2, and Week 3. Week 4 depicts green and yellow tablets, labeled as such. The diagram includes directional arrows and dosing information for desogestrel 0.15 mg and ethinyl estradiol 0.03 mg tablets.*
FDA Label Image

Volnea-new-carton (Volnea Carton 2)

Volnea-new-carton (Volnea Carton 2)
Volnea kit containing Desogestrel and Ethinyl Estradiol Tablets, USP, 0.15 mg/0.02 mg and 0.01 mg strengths. The carton shows the labeler Xiromed, LLC, with a 28-day regimen in 3 blister packs of 28 tablets each (21 white, 2 green, 5 yellow). It includes dosing instructions and storage conditions. Product NDC 70700-122.*
FDA Label Image

Structure Formula (Image 01)

Structure Formula (Image 01)
Chemical structures of Desogestrel and Ethinyl Estradiol are shown, including their molecular formulas C22H30O and C20H24O2 respectively, depicting their steroidal frameworks with associated functional groups.*
FDA Label Image

Volnea-figure-1.jpg (Volnea Figure 1)

Volnea-figure-1.jpg (Volnea Figure 1)
A bar graph depicting mortality rates (number of deaths per 100,000 woman-years) across different age groups (15-24, 25-34, 35-44, 45+) for four categories: ever-users (non-smokers), ever-users (smokers), controls (non-smokers), and controls (smokers). The chart shows mortality rates increasing with age in all groups, with notably higher rates for ever-users who smoke in the older age groups.*
FDA Label Image

Volnea-blister-1.jpg (Volnea Blister 1)

Volnea-blister-1.jpg (Volnea Blister 1)
Packaging label for Volnea Desogestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.02 mg and 0.01 mg, in a kit format. The label includes a weekly pill calendar with 28 circular indentations arranged by day of the week across four weeks to track daily tablet use. The labeler is Xiromed, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.